Earnings summaries and quarterly performance for Schrodinger.
Executive leadership at Schrodinger.
Ramy Farid
Detailed
President and Chief Executive Officer
CEO
KA
Karen Akinsanya
Detailed
President of R&D, Therapeutics
MD
Margaret Dugan
Detailed
Chief Medical Officer
PL
Patrick Lorton
Detailed
Executive Vice President and Chief Operating Officer, Software; Chief Technology Officer
RJ
Richie Jain
Detailed
Executive Vice President, Chief Financial Officer and Treasurer
RA
Robert Abel
Detailed
Executive Vice President and Chief Scientific Officer, Platform
YT
Yvonne Tran
Detailed
Executive Vice President and Chief Legal Officer; Chief People Officer
Board of directors at Schrodinger.
AO
Arun Oberoi
Detailed
Director
Bv
Bridget van Kralingen
Detailed
Director
GG
Gary Ginsberg
Detailed
Director
GS
Gary Sender
Detailed
Director
JC
Jeffrey Chodakewitz
Detailed
Director
ML
Michael Lynton
Detailed
Chairman of the Board
NT
Nancy Thornberry
Detailed
Director
RF
Richard Friesner
Detailed
Director
RK
Rosana Kapeller-Libermann
Detailed
Director
Research analysts who have asked questions during Schrodinger earnings calls.
BS
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
6 questions for SDGR
Also covers: ABCL, ABSI, ARWR +20 more
Michael Ryskin
Bank of America Merrill Lynch
5 questions for SDGR
Also covers: A, ALGN, AVTR +29 more
Scott Schoenhaus
KeyBanc Capital Markets
5 questions for SDGR
Also covers: ALIT, CERT, DOCS +9 more
ES
Evan Seigerman
BMO Capital Markets
4 questions for SDGR
Also covers: ABBV, AMGN, ARVN +15 more
MF
Mani Foroohar
Leerink Partners
4 questions for SDGR
Also covers: ADVM, ALNY, ARWR +9 more
MH
Matthew Hewitt
Craig-Hallum Capital Group LLC
4 questions for SDGR
Also covers: ACET, APYX, BHST +21 more
DL
David Lebowitz
Citigroup Inc.
3 questions for SDGR
Also covers: ALNY, ARWR, ASND +11 more
VP
Vikram Purohit
Morgan Stanley
3 questions for SDGR
Also covers: ABSI, ARGX, ARQT +11 more
Michael Yee
Jefferies
2 questions for SDGR
Also covers: ABBV, ALLO, AMGN +19 more
A
Alexa
Bank of America
1 question for SDGR
CS
Chris Shibutani
Goldman Sachs Group, Inc.
1 question for SDGR
Also covers: ABBV, ALKS, BMY +11 more
Conor MacKay
BMO Capital Markets
1 question for SDGR
Also covers: ABCL, AMGN, ARVN +1 more
JC
Joseph Catanzaro
Wolfe Research, LLC
1 question for SDGR
Also covers: AADI, CPRX, CRDF +8 more
KY
Kailun Ying
UBS
1 question for SDGR
KY
Kaiyue Yang
Jefferies
1 question for SDGR
Also covers: IVVD
Lili Nsongo
Leerink Partners
1 question for SDGR
Also covers: ARCT
MH
Malcolm Hoffman
BMO Capital Markets
1 question for SDGR
Also covers: ABCL, ACAD, BMY +2 more
Morgan
Morgan Stanley
1 question for SDGR
Also covers: ARGX
Sean Laaman
Morgan Stanley & Co.
1 question for SDGR
Also covers: ACAD, ARGX, AXSM +8 more
SL
Sean Lehmann
Morgan Stanley
1 question for SDGR
Also covers: BMRN
T
Taltz
Craig-Hallum
1 question for SDGR
Recent press releases and 8-K filings for SDGR.
Schrodinger Discusses Transition to Hosted Services, ACV Reporting, and Growth Drivers
SDGR
Accounting Changes
Guidance Update
New Projects/Investments
- Schrodinger is transitioning to hosted software services, which will lead to a decline in reported revenue, gross margins, and Adjusted EBITDA this year due to ratable revenue recognition, though it has no impact on cash flow. Annual Contract Value (ACV) will be the primary operating metric for investors during this period.
- Key growth drivers for the software business include the recently launched predictive toxicology offering, continued scale-up of platform usage by pharma companies, and expansion into biologics and material science applications.
- For its therapeutics pipeline, Schrodinger plans to partner its internal assets for mid and late-stage development, with data for SGR-3515 expected in Q2 this year. The company will focus on generating milestones and royalties from collaborations, with five programs in $5 billion-plus markets offering high single-digit to low double-digit royalties.
21 hours ago
Schr\u00f6dinger Discusses Transition to Hosted Services, Impact on Revenue, and Growth Initiatives
SDGR
Accounting Changes
Guidance Update
Product Launch
- Schr\u00f6dinger is transitioning to hosted services, which will result in an accounting difference where revenue is recognized ratably over the contract term, unlike on-premise software.
- This transition is expected to cause a temporary decline in revenue, gross margins, and Adjusted EBITDA this year, with the unrecognized revenue to be picked up in the 2027 reporting year. Annual Contract Value (ACV) will serve as the primary operating metric for investors due to this revenue noise.
- The company anticipates growth from newly launched products, including Predictive Toxicology, which is out of beta, and continued expansion into Biologics and Material Science applications.
- For its therapeutics pipeline, Schr\u00f6dinger plans to present SGR-3515 data in Q2 this year and will focus on partnering for mid and late-stage development of its assets.
21 hours ago
Schrödinger Discusses Transition to Hosted Services, Predictive Toxicology Growth, and Therapeutics Pipeline Strategy
SDGR
Accounting Changes
Guidance Update
Product Launch
- Schrödinger is transitioning to hosted services, which will result in an expected revenue decline this year due to accounting changes, but has no impact on cash flow. ACV (Annual Contract Value) will serve as the primary operating metric for investors, with revenue expected to recover in 2027.
- The predictive toxicology offering has exited beta and is anticipated to drive growth this year and into the future, addressing a significant drug discovery challenge by enabling early toxicity prediction and aligning with FDA initiatives.
- The company plans to advance its therapeutics pipeline, including SGR-1505 and SGR-3515, through partnerships, with SGR-3515 data expected in Q2 this year. Five collaboration programs are in $5 billion-plus markets, offering high single-digit to low double-digit royalties.
- New partnerships, such as with Lilly's TuneLab, aim to broaden the platform's reach by providing biotechs access to advanced machine learning toxicology models, fostering wider adoption and growth.
- Schrödinger is expanding its platform into biologics (e.g., LiveDesign for Biologics) and material science (e.g., battery chemistry, crystal structure prediction), leveraging its physics-based methods and AI to tap into new markets and drive future growth.
21 hours ago
Schrödinger Reports Q4 and Full Year 2025 Results, Outlines 2026 Guidance and 2028 Objectives
SDGR
Earnings
Guidance Update
Accounting Changes
- Schrödinger reported $256 million in total revenue for full year 2025, representing 23% growth, with a net loss of $103 million and a strong cash position of $402 million at year-end.
- The company is accelerating its transition to a primarily hosted software model, aiming for 75% hosted revenue by 2028, which will lead to more predictable revenue recognition over time but may cause near-term variability in reported software revenue without impacting ACV or cash flows.
- For full year 2026, Schrödinger expects software ACV to be between $218 million and $228 million, representing 10%-15% growth, and anticipates drug discovery revenue between $55 million and $65 million.
- Schrödinger is targeting positive adjusted EBITDA by the end of 2028, supported by software growth, the hosted transition, and continued operating expense discipline, with operating expenses expected to be less than 2025.
7 days ago
Schrodinger Reports Strong 2025 Results and Outlines 2026 Outlook and 2028 Objectives
SDGR
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Schrodinger reported $256 million in total revenue for FY 2025, marking a 23% growth, with software revenue at $200 million (+11%) and drug discovery revenue at $56 million. The company concluded the year with a strong balance sheet, holding $402 million in cash and equivalents.
- For 2026, the company projects software ACV to be $218-$228 million, reflecting 10-15% growth over 2025, and anticipates drug discovery revenue between $55-$65 million. Operating expenses are expected to be less than 2025.
- A key strategic priority is accelerating the transition to hosted software deployments, which represented 23% of software revenue in 2025. This move aims to simplify offerings, enhance efficiencies, and generate more predictable revenue, with a goal to reach 75% hosted revenue by 2028.
- By the end of 2028, Schrodinger targets 10-15% annual software ACV growth, $50 million in annual drug discovery revenue, a return to high 70s gross margin, and achieving positive adjusted EBITDA.
7 days ago
Schrödinger Announces Q4 and Full Year 2025 Results, Provides 2026 ACV Guidance and 2028 Targets
SDGR
Earnings
Guidance Update
Accounting Changes
- Schrödinger reported full-year 2025 revenue of $256 million, a 23% increase year-over-year, with software revenue at $199.5 million and drug discovery revenue at $56.4 million. The company ended the year with over $400 million in cash.
- Q4 2025 software revenue decreased 13% to $69.3 million compared to Q4 2024, primarily due to an accelerated transition to a hosted model, which defers revenue recognition for multi-year deals.
- The company provided 2026 Software Annual Contract Value (ACV) guidance of $218 million to $220 million, representing 9%-14% year-over-year growth.
- Schrödinger aims to achieve positive adjusted EBITDA by the end of 2028, supported by annual software growth of 10%-15% and approximately $50 million in annual drug discovery revenue. A strategic shift is underway to transition approximately 75% of software revenue to a hosted model by 2028.
7 days ago
Schrödinger Reports Q4 2025 Results and Provides 2026 Outlook
SDGR
Earnings
Guidance Update
Accounting Changes
- Schrödinger reported $256 million in total revenue for 2025, representing 23% growth, with a net loss of $103 million.
- The company's software business generated $199.5 million in revenue and $198.5 million in annual contract value (ACV) in 2025, with total ACV growing 4% year-over-year.
- For 2026, Schrödinger expects software ACV to be in the range of $218 million-$228 million, reflecting 10%-15% growth, and drug discovery revenue between $55 million-$65 million.
- Schrödinger is accelerating its transition to a hosted software model, aiming for 75% of software revenue to be hosted by 2028, and targets achieving positive adjusted EBITDA by the end of 2028.
- The company maintains a strong cash position of over $400 million to support growth and its path to positive adjusted EBITDA.
7 days ago
Schrödinger Reports Q4 and Full-Year 2025 Financial Results
SDGR
Earnings
Guidance Update
New Projects/Investments
- Schrödinger reported full-year 2025 total revenue of $255.9 million, a 23.3% increase over 2024, with software revenue growing 10.6% to $199.5 million and drug discovery revenue at $56.4 million.
- For the fourth quarter of 2025, total revenue was $87.2 million, a 1.2% decrease, and software revenue decreased 13% to $69.3 million, primarily due to accelerated recognition of upfront revenue from multi-year agreements in 2024. The company reported net income of $32.5 million for Q4 2025.
- Full-year 2025 Adjusted EBITDA was $(114.9) million, while Q4 2025 Adjusted EBITDA was $(5.2) million. The company ended 2025 with approximately $402.3 million in cash, cash equivalents, restricted cash, and marketable securities.
- Schrödinger is accelerating its transition to hosted software, which is expected to cause short-to-medium term declines in software revenue but no impact on ACV or cash flow. The company aims to achieve positive adjusted EBITDA by the end of 2028.
- For fiscal year 2026, the company expects Software ACV to range from $218 million to $228 million (10-15% growth) and drug discovery revenue between $55 million and $65 million.
7 days ago
Schrödinger Updates on 2025 Progress and Outlines 2026 Priorities
SDGR
New Projects/Investments
Product Launch
Guidance Update
- Schrödinger announced new strategic agreements with Lilly and Manas AI, integrating its computational platform and physics-based modeling solutions.
- In 2025, the company launched a beta version of its predictive toxicology initiative and an AI-powered conversational interface in Maestro.
- The proprietary therapeutic candidate SGR-1505 (MALT1 inhibitor) showed encouraging initial Phase 1 clinical data and received FDA Fast Track and Orphan Drug Designations for Waldenström macroglobulinemia.
- For 2026, key priorities include completing Phase 1 data packages for SGR-1505 and SGR-3515, presenting initial SGR-3515 data in the first half of 2026, and exploring strategic partnerships for these programs.
Jan 12, 2026, 1:30 PM
Schrödinger Partners with Lilly to Integrate TuneLab Platform into LiveDesign
SDGR
Product Launch
New Projects/Investments
- Schrödinger announced a collaboration with Eli Lilly and Company (Lilly) to make the Lilly TuneLab platform available in LiveDesign, Schrödinger's enterprise informatics platform.
- This partnership aims to accelerate drug discovery and development by providing access to TuneLab's advanced artificial intelligence (AI) capabilities within LiveDesign.
- LiveDesign will serve as a priority interface for participating biotech companies to access TuneLab workflows.
- TuneLab employs a privacy-first federated learning approach, allowing Lilly and partner companies to utilize the platform while keeping their proprietary data separate and private.
Jan 9, 2026, 12:00 PM
Quarterly earnings call transcripts for Schrodinger.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more